Podium to Practice: EHA 2026 – Multiple Myeloma: CEPHEUS STUDY

Podium to Practice: EHA 2026 – Multiple Myeloma: CEPHEUS STUDY

Podium to Practice: EHA 2026

Studies / Trials Discussed

S196 – DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF TRANSPLANT-INELIGIBLE PATIENTS IN THE PHASE 3 CEPHEUS STUDY

Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

S196 – DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF TRANSPLANT-INELIGIBLE PATIENTS IN THE PHASE 3 CEPHEUS STUDY

Abstract of the paper or summary description of the presentation:

LB5008 – TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE PHASE 2 IMMUNOPRISM TRIAL

Tagged